Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Fastly Inc (FSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Fastly Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Fastly Inc trades at $19 (market cap $2.91B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Fastly Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | FSLY | |
|---|---|---|
Market Cap | $4.49B | $2.91B |
Sector | Health | Technology |
52-Week High | $28.06 | $33.50 |
52-Week Low | $20.06 | $6.36 |
Enterprise Value | $3.69B | $2.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Fastly (FSLY) trades at $18.59, up 2.54% with a bullish technical signal and positive earnings momentum, having beaten EPS estimates for three consecutive quarters. The company shows improving revenue growth (20% YoY in Q1 2026) and margin expansion, though it remains unprofitable with a -15.79% net income margin. Recent positive developments include Gartner recognition and strategic AI partnerships, while analyst consensus leans neutral with a $25.80 price target representing 39% upside potential.
Fastly presents a growth opportunity in edge cloud infrastructure with strong AI-driven demand, but carries execution risks amid ongoing losses. The stock's valuation at 4.18x sales appears reasonable for a 20% grower, though competitive pressures and high infrastructure spending require careful monitoring. Current technical strength near key support at $18 suggests near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →
